Manufactured by Eli Lilly
First of its kind: Foundayo is the only GLP-1 pill for weight loss that can be taken at any time of day without food or water restrictions. Unlike Wegovy Pill (oral semaglutide, FDA-approved December 2025) and Rybelsus (oral semaglutide for type 2 diabetes), Foundayo uses a novel small-molecule compound (orforglipron). Launched April 2026 with a list price of $649/month; LillyDirect self-pay from $149-$349/month depending on dose; Savings Card for commercial insurance as low as $25/month.
First oral GLP-1 pill FDA-approved for chronic weight management. List price $649/mo; LillyDirect self-pay starts at $149/mo; Savings Card $25/mo for eligible commercial insurance.
FDA Status
FDA Approved
Route
oral
Approved Indications
Typical Dose Range
0.8mg - 17.2mg daily
Dosing is determined by your prescribing provider based on your individual needs. Most GLP-1 medications follow a gradual titration schedule, starting at a low dose and increasing over several weeks to reduce side effects.
Branded (Retail)
$649/mo
Savings Program
$149/mo
Prices are estimates and may vary by pharmacy, location, and insurance coverage. Contact your provider for accurate pricing.
This is not a complete list of side effects. Talk to your healthcare provider about what to expect and when to seek medical attention.
This site is for educational purposes only and is not medical advice. Always consult a healthcare provider before starting any medication. Full disclaimer
Eli Lilly's oral GLP-1 pill Foundayo outperformed Novo Nordisk's oral semaglutide in head-to-head diabetes trials, setting up a second FDA submission by month's end.
The DoseFDA seeks public feedback today on controversial Priority Voucher program that enabled record 50-day approval of Eli Lilly's GLP-1 pill Foundayo.
The DoseFDA requests extensive safety studies for Eli Lilly's newly approved Foundayo (orforglipron) due to limited long-term data on the first small-molecule GLP-1 weight loss pill.
The DoseEli Lilly's Foundayo becomes first GLP-1 pill that can be taken anytime without food restrictions, launching at $149/month through record-fast FDA approval.
